Category Archives: Cancer Treatment

Results in Clinical Trials May Not Represent Results in Real Life Treatment

For patients who choose to undergo immunotherapy for cancer, new medications are often available more quickly than usual. In fact, a new study found that new medications used in immunotherapy start being used faster than the standard practice for other new medical treatments. Some of this is due to the results of clinical trials, but there are a few potential problems to consider.

Age of Clinical Trial Participants

One of the most notable differences between clinical trial participants and cancer patients is age. Those who took part in clinical trials for immunotherapy treatments tended to be younger than those treated in clinical practice. Clinical trial participants were mainly in their late 50s or early 60s, while cancer patients treated clinically were 65 and older. Knowing more about how real world populations respond to newly adopted medications for cancer involves doing more research.

Early vs. Later Clinical Trials

Another problem with beginning the use of immunotherapy medications more quickly than usual is the risk of having later clinical trials show different results compared to early trials. Fast approval is often based on the findings of early clinical trials, but there is a risk of having later trials find that medications are harmful or not as effective.

Recommendations for Rapid Adoption

Experts recommend running clinical trials that include participants who are similar to real world populations of cancer patients. Doing this should help provide findings that better reflect results for real world populations. Other recommendations include avoiding basing approval on small studies, the use of atypical patient populations, and studies that don’t compare the treatment with current alternative options that are available.

For more information on immunotherapy for cancer, please contact Issels® today. We can provide additional information on this type of cancer treatment.

Steer Clear of These Foods While in Traditional Cancer Treatment

Herbs and other supplements can provide an added boost for patients with cancer. In many cases, alternative cancer therapies can succeed where standard therapies have failed.

However, in some cases, complementary medicines that are recommended for some patients can actually have adverse effects on certain other patients. An herb may be excellent for one form of cancer and hazardous for another. In all cases, patients should confirm recommendations with a doctor before taking supplements.

These products may not be prescription drugs, but they do have a powerful ability to interact with chemotherapy, radiation treatments, and anti-cancer medicines.

Below are common supplements with anti-cancer properties that may also cause serious problems if taken during other treatments. Consult the American Cancer Society website or other trusted sources for a helpful guide to vitamins, minerals, and herbal medicines.

1. Fish oil: May induce bleeding if you have a low platelet count.

2. Ginger: Also may induce bleeding.

3. Turmeric: Could decrease the effectiveness of chemotherapy — or increase the effects, with toxic results.

4. Coenzyme Q10: Antioxidant properties may interfere with chemotherapy and radiation.

5. Milk thistle: May affect estrogen levels, which could pose an issue for breast or ovarian cancer.

6. Licorice: Also may affect estrogen levels.

7. Green tea: Negates the benefits of certain anti-cancer drugs.

8. Reishi mushroom: May interfere with certain drugs or chemotherapy.

9. Astragalus: May interfere with certain immunosuppressants.

10. Acidophilus: May cause infections or other problems if taken during chemotherapy.

Despite the risks for some patients, these substances do have successful results for many people. Issels® Integrative Immuno-Oncology can always help with information about alternative cancer treatment.

Low Protein Diets May Lower the Risk of Cancer

In recent years, Keto, Paleo and other high-protein diets have been grabbing all the headlines. Despite their popularity for weight loss, a low-protein diet may be more valuable in preventing tumors, according to cancer immunotherapy studies.

Protein and the Immune System

Yes-associated protein, referred to as YAP, is found in the population of T-cells, which are the warriors of the immune system. A team of scientists conducted research to explore the effects of YAP in the immune system’s response to cancer.

Studies were done using a group of mice that were genetically engineered to have low YAP in many of the T-cell populations. In particular, research focused on the relationship between YAP and Tregs, a regulatory T-cell that’s instrumental in preventing autoimmune diseases but interferes with cancer immunotherapy.

Results indicated that YAP activity suppresses T-cell function. When YAP levels are reduced or eliminated, it serves to stimulate T-cell function, allowing them to infiltrate solid tumors and block additional tumor growth.

Since Tregs inhibit the effects of immunotherapy, targeting YAP activity toward Tregs can be a positive use. The study, which was published in Journal of Cancer Discovery, offers promising implications for new methods to improve patient responses to immunotherapy.

Potential Benefits of Low-Protein Diets

In addition to possible applications in cancer treatment, low-protein diets have been used to improve other health conditions.

  • High levels of protein put stress on the liver and kidneys, so a low-protein diet can aid people suffering from diseases of these organs.
  • Lower levels of protein may also reduce the risk of diabetes and heart disease.
  • A low-protein diet can prevent build-up of urea, which is waste filtered by the kidneys.

Issels®: Leaders in Cancer Immunotherapy

Our personalized, non-toxic immunotherapy programs have given new hope to many patients. Contact us to learn more.

 

Careful with Antibiotics During Cancer Treatment!

Doctors always take care when prescribing combinations of drugs due to possible negative interactions. It’s not surprising that mounting evidence indicates the complex balance of targeted cancer treatment can be upset by use of antibiotics.

Disrupting the Body’s Natural Defenses

According to results of a study conducted at the Georgia Cancer Center, this problem stems from the effect of antibiotics on gut microbiota, the network of bacteria, viruses and fungi that resides in the digestive tract. These “good” germs aid with digestion and protect our system from “bad” germs.

In the process of killing off microorganisms that cause infections, antibiotics also destroy large amounts of gut bacteria. As a result, patients on a course of antibiotics often experience nausea, vomiting, diarrhea and other gastrointestinal symptoms.

The Connection Between Gut Bacteria and Cancer Treatment

Dr. Gang Zhou, corresponding author of the study, explained that certain bacteria in the microbiota are necessary to activate the T-cells involved in cancer treatment known as adoptive T-cell therapy. A newer form of treatment called CAR T-cell therapy appears to be resistant to the antibiotic effect because it works on its own, with little reliance on the immune system.

Co-author Dr. Locke Bryan pointed out that antibiotics are often used in conjunction with chemotherapy. This traditional cancer treatment lowers white blood cell counts to the point where there’s no defense against bacteria, and an infection can be lethal to an already weakened immune system.

Individualized Treatment Plans for Specific Needs

Our personally tailored immunobiologic core treatments are designed to remove or repair factors that inhibit the body’s natural defense mechanisms. Contact us for more information.

Cancer Genome Atlas Reveals an Inherent Weakness in Tumor Cells

In genetic analyses of cancer cells, scientists have focused largely on the DNA component. Thanks to a genetic database compiled over 13 years, researchers have discovered that information found in RNA may possibly enable expanded use of cancer immunotherapy.

What Is the Cancer Genome Atlas?

The Cancer Genome Atlas was a joint project between the US National Cancer Institute’s Center for Cancer Genomics and the National Human Genome Research Institute. Genetic information from tumor cells representing 33 types of cancer was gathered from thousands of patients.

In 2017, the project came to its planned conclusion. Going forward, scientists will continue to mine the data in search of applications toward improved prevention, detection and treatment of cancer.

A New Clue in Cancer Detection

Just after the conclusion of the Atlas project, a research team headed up by Gunnar Rätsch, professor of biomedical informatics at ETH Zurich, took on an analysis of the database. They were aided by a supercomputer that was capable of processing several hundred terabytes of raw data.

RNA, which “transcribes” DNA, first undergoes a series of changes known as alternative splicing. In this process, specialized enzymes remove sections from an RNA molecule and join the remaining sides together.

While alternative splicing can take many variations, Rätsch’s team discovered tens of thousands of previously undescribed forms of splicing that were present in cancer cells. Up to 75 percent of the cases studied contained these variations, so the team is hopeful that further research could lead to using these markers for expanded cancer immunotherapy treatment.

State-of-the-Art Cancer Immunotherapy

At Issels®, we have always remained in the forefront of cancer studies and treatments. Contact us to learn more about our personalized, non-toxic programs and how they have helped patients with advanced cancer patients achieve long-term remission.

New Urine Test May Allow Dismissal of Prostate Biopsy

Urine samples can be used to detect a wide range of conditions such as diabetes, pregnancy and drug abuse. Researchers are now working on developing a urine “sniff test” that can help reduce the number of unnecessary prostate cancer biopsies.

Diagnosing Prostate Cancer

Among men in the United States, cases of prostate cancer are second only to skin cancer. Approximately one in seven men will require cancer treatment for the disease at some point in their lifetime.

One of the signs of prostate cancer is an elevated blood level of prostate-specific antigen (PSA). Unfortunately, unrelated conditions can also cause high PSA levels, so a biopsy is necessary for a specific diagnosis.

The Nose Knows

A study showed that dogs could smell the presence of volatile organic compounds (VOCs) in the urine of men with prostate cancer at 98 percent accuracy, prompting a team at Indiana University-Purdue University Indianapolis to investigate further.

After collecting urine samples from 100 men undergoing prostate biopsies and neutralizing the pH to prevent degradation, the team discovered that a particular set of VOCs was present in 90 percent of the men who were diagnosed with prostate cancer but absent in the men who were cancer-free.

The researchers plan to validate their findings with a large-scale study and comparison to the results with dogs. If all goes well, they project that a version of the sniff test will be available for clinical use within a few years.

Personalized Cancer Treatment at Issels®

Our individually developed immunotherapy programs are based on special testing to identify your particular needs. Contact us for more information.